{"id":63166,"date":"2026-04-14T23:45:02","date_gmt":"2026-04-14T15:45:02","guid":{"rendered":"https:\/\/flcube.com\/?p=63166"},"modified":"2026-04-14T23:45:03","modified_gmt":"2026-04-14T15:45:03","slug":"winhealth-pharma-licenses-worlds-first-oral-arsenic-trioxide-arsenol-for-mainland-china-apl-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63166","title":{"rendered":"WinHealth Pharma Licenses World&#8217;s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment"},"content":{"rendered":"\n<p><strong>Hong Kong WinHealth Pharma Group<\/strong> has entered a licensing agreement with fellow Hong Kong firm <strong>Jacobson Pharma Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2633:HKG\">HKG: 2633<\/a>) to develop and commercialize <strong>Arsenol (oral arsenic trioxide solution)<\/strong> in <strong>mainland China<\/strong>. The therapy, developed from research at the <strong>Li Ka Shing Faculty of Medicine, University of Hong Kong<\/strong>, is the <strong>first prescription drug fully researched and developed by Hong Kong, China<\/strong>, and represents the <strong>world&#8217;s first oral arsenic trioxide formulation<\/strong> for <strong>acute promyelocytic leukemia (APL)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensee<\/strong><\/td><td>Hong Kong WinHealth Pharma Group<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>Jacobson Pharma Corporation (HKG: 2633)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Arsenol (oral arsenic trioxide solution)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China<\/td><\/tr><tr><td><strong>Origin<\/strong><\/td><td>Li Ka Shing Faculty of Medicine, University of Hong Kong<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>Approved therapy with orphan drug designations from FDA and EMA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-clinical-excellence\">Drug Profile &amp; Clinical Excellence<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Class:<\/strong> Oral arsenic trioxide \u2013 world&#8217;s first oral formulation of this established APL therapy<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Acute promyelocytic leukemia (APL) \u2013 rare hematologic malignancy representing 5\u201320% of adult AML cases<\/li>\n\n\n\n<li><strong>Epidemiology:<\/strong> Annual incidence of 1\u20137.4 cases per million people globally<\/li>\n\n\n\n<li><strong>Clinical Outcomes:<\/strong><\/li>\n\n\n\n<li>Overall survival rates exceeding <strong>97%<\/strong> across multiple clinical studies<\/li>\n\n\n\n<li><strong>100% five-year leukemia-free survival<\/strong> in first-line treatment of newly diagnosed patients<\/li>\n\n\n\n<li><strong>100% five-year overall survival<\/strong> in first-line treatment studies<\/li>\n\n\n\n<li><strong>Regulatory Recognition:<\/strong> Orphan drug designations from both U.S. FDA and European EMA<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-innovation-significance\">Innovation Significance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scientific-achievement\">Scientific Achievement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hong Kong Innovation Milestone:<\/strong> First prescription drug entirely researched and developed in Hong Kong<\/li>\n\n\n\n<li><strong>Formulation Breakthrough:<\/strong> Transforms traditional intravenous arsenic trioxide into convenient oral administration<\/li>\n\n\n\n<li><strong>Patient-Centric Design:<\/strong> Eliminates need for hospital-based IV infusions, enabling outpatient treatment<\/li>\n\n\n\n<li><strong>Therapeutic Optimization:<\/strong> Maintains efficacy while improving quality of life and treatment accessibility<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-impact\">Clinical Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Survival Revolution:<\/strong> Transforms APL from highly fatal to highly curable leukemia subtype<\/li>\n\n\n\n<li><strong>Treatment Simplification:<\/strong> Oral administration reduces healthcare system burden and patient inconvenience<\/li>\n\n\n\n<li><strong>Global Standard:<\/strong> Establishes new benchmark for APL treatment worldwide<\/li>\n\n\n\n<li><strong>Rare Disease Focus:<\/strong> Addresses critical unmet need in orphan disease with limited therapeutic options<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-winhealth-pharma\">For WinHealth Pharma<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Premium Asset Acquisition:<\/strong> Secures exclusive mainland China rights to breakthrough therapy<\/li>\n\n\n\n<li><strong>Oncology Portfolio Enhancement:<\/strong> Establishes leadership position in hematologic malignancies<\/li>\n\n\n\n<li><strong>Orphan Drug Expertise:<\/strong> Builds capabilities in rare disease development and commercialization<\/li>\n\n\n\n<li><strong>Hong Kong-China Bridge:<\/strong> Leverages cross-border innovation ecosystem<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-mainland-china-market\">For Mainland China Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treatment Access:<\/strong> Provides Chinese APL patients access to world-leading oral therapy<\/li>\n\n\n\n<li><strong>Healthcare Efficiency:<\/strong> Reduces hospitalization requirements and associated costs<\/li>\n\n\n\n<li><strong>Clinical Guidelines:<\/strong> Potential to become standard-of-care for APL treatment in China<\/li>\n\n\n\n<li><strong>Innovation Adoption:<\/strong> Demonstrates China&#8217;s openness to adopting cutting-edge Hong Kong-developed therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>APL Patient Population:<\/strong> Estimated 1,500\u20132,000 new APL cases annually in mainland China<\/li>\n\n\n\n<li><strong>Pricing Premium:<\/strong> Orphan drug status and superior outcomes support premium reimbursement positioning<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Limited competition due to specialized nature of APL treatment<\/li>\n\n\n\n<li><strong>Reimbursement Pathway:<\/strong> National Reimbursement Drug List (NRDL) inclusion likely given clinical excellence<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<p>WinHealth Pharma will now pursue regulatory approval in mainland China, leveraging the drug&#8217;s established safety and efficacy profile and existing international regulatory recognitions to potentially accelerate the approval process.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory pathways, market opportunities, and commercial expectations for Arsenol in mainland China. Actual results may differ due to risks including regulatory decisions, competitive dynamics, reimbursement negotiations, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hong Kong WinHealth Pharma Group has entered a licensing agreement with fellow Hong Kong firm&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63167,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,3925,3926,2095],"class_list":["post-63166","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-hkg-2633","tag-jacobson-pharma","tag-winhealth-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WinHealth Pharma Licenses World&#039;s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hong Kong WinHealth Pharma Group has entered a licensing agreement with fellow Hong Kong firm Jacobson Pharma Corporation (HKG: 2633) to develop and commercialize Arsenol (oral arsenic trioxide solution) in mainland China. The therapy, developed from research at the Li Ka Shing Faculty of Medicine, University of Hong Kong, is the first prescription drug fully researched and developed by Hong Kong, China, and represents the world&#039;s first oral arsenic trioxide formulation for acute promyelocytic leukemia (APL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63166\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WinHealth Pharma Licenses World&#039;s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment\" \/>\n<meta property=\"og:description\" content=\"Hong Kong WinHealth Pharma Group has entered a licensing agreement with fellow Hong Kong firm Jacobson Pharma Corporation (HKG: 2633) to develop and commercialize Arsenol (oral arsenic trioxide solution) in mainland China. The therapy, developed from research at the Li Ka Shing Faculty of Medicine, University of Hong Kong, is the first prescription drug fully researched and developed by Hong Kong, China, and represents the world&#039;s first oral arsenic trioxide formulation for acute promyelocytic leukemia (APL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63166\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T15:45:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T15:45:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1408.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63166#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63166\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WinHealth Pharma Licenses World&#8217;s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment\",\"datePublished\":\"2026-04-14T15:45:02+00:00\",\"dateModified\":\"2026-04-14T15:45:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63166\"},\"wordCount\":532,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63166#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1408.webp\",\"keywords\":[\"Cancer\",\"HKG: 2633\",\"Jacobson Pharma\",\"WinHealth Pharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63166#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63166\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63166\",\"name\":\"WinHealth Pharma Licenses World's First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63166#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63166#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1408.webp\",\"datePublished\":\"2026-04-14T15:45:02+00:00\",\"dateModified\":\"2026-04-14T15:45:03+00:00\",\"description\":\"Hong Kong WinHealth Pharma Group has entered a licensing agreement with fellow Hong Kong firm Jacobson Pharma Corporation (HKG: 2633) to develop and commercialize Arsenol (oral arsenic trioxide solution) in mainland China. The therapy, developed from research at the Li Ka Shing Faculty of Medicine, University of Hong Kong, is the first prescription drug fully researched and developed by Hong Kong, China, and represents the world's first oral arsenic trioxide formulation for acute promyelocytic leukemia (APL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63166#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63166\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63166#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1408.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1408.webp\",\"width\":1080,\"height\":608,\"caption\":\"WinHealth Pharma Licenses World's First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63166#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WinHealth Pharma Licenses World&#8217;s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WinHealth Pharma Licenses World's First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Hong Kong WinHealth Pharma Group has entered a licensing agreement with fellow Hong Kong firm Jacobson Pharma Corporation (HKG: 2633) to develop and commercialize Arsenol (oral arsenic trioxide solution) in mainland China. The therapy, developed from research at the Li Ka Shing Faculty of Medicine, University of Hong Kong, is the first prescription drug fully researched and developed by Hong Kong, China, and represents the world's first oral arsenic trioxide formulation for acute promyelocytic leukemia (APL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63166","og_locale":"en_US","og_type":"article","og_title":"WinHealth Pharma Licenses World's First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment","og_description":"Hong Kong WinHealth Pharma Group has entered a licensing agreement with fellow Hong Kong firm Jacobson Pharma Corporation (HKG: 2633) to develop and commercialize Arsenol (oral arsenic trioxide solution) in mainland China. The therapy, developed from research at the Li Ka Shing Faculty of Medicine, University of Hong Kong, is the first prescription drug fully researched and developed by Hong Kong, China, and represents the world's first oral arsenic trioxide formulation for acute promyelocytic leukemia (APL).","og_url":"https:\/\/flcube.com\/?p=63166","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T15:45:02+00:00","article_modified_time":"2026-04-14T15:45:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1408.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63166#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63166"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WinHealth Pharma Licenses World&#8217;s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment","datePublished":"2026-04-14T15:45:02+00:00","dateModified":"2026-04-14T15:45:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63166"},"wordCount":532,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63166#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1408.webp","keywords":["Cancer","HKG: 2633","Jacobson Pharma","WinHealth Pharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63166#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63166","url":"https:\/\/flcube.com\/?p=63166","name":"WinHealth Pharma Licenses World's First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63166#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63166#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1408.webp","datePublished":"2026-04-14T15:45:02+00:00","dateModified":"2026-04-14T15:45:03+00:00","description":"Hong Kong WinHealth Pharma Group has entered a licensing agreement with fellow Hong Kong firm Jacobson Pharma Corporation (HKG: 2633) to develop and commercialize Arsenol (oral arsenic trioxide solution) in mainland China. The therapy, developed from research at the Li Ka Shing Faculty of Medicine, University of Hong Kong, is the first prescription drug fully researched and developed by Hong Kong, China, and represents the world's first oral arsenic trioxide formulation for acute promyelocytic leukemia (APL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63166#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63166"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63166#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1408.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1408.webp","width":1080,"height":608,"caption":"WinHealth Pharma Licenses World's First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63166#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WinHealth Pharma Licenses World&#8217;s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1408.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63166"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63166\/revisions"}],"predecessor-version":[{"id":63168,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63166\/revisions\/63168"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63167"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}